Evidence map›Paper›PMID 28441087›Full record

ArticleMedical decision making : an international journal of the Society for Medical Decision Making2017

Using the Payoff Time in Decision-Analytic Models: A Case Study for Using Statins in Primary Prevention.

Alexander Thompson, Bruce Guthrie, Katherine Payne

Abstract read
In one paragraph

Article in Medical decision making : an international journal of the Society for Medical Decision Making, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Population turnover and leakage in commercial ACOs.The American journal of managed care · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alexander ThompsonManchester Centre for Health Economics, University of Manchester, Manchester, UK (AT, KP).
Bruce GuthriePopulation Health Sciences Division, The University of Dundee, UK (BG).
Katherine PayneManchester Centre for Health Economics, University of Manchester, Manchester, UK (AT, KP).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe payoff time represents an estimate of when the benefits of an intervention outweigh the costs. It is particularly useful for benefit-harm decision making for interventions that have deferred benefits but upfront harms. The aim of this study was to expand the application of the payoff time and provide an example of its use within a decision-analytic model.

methodsThree clinically relevant patient vignettes based on varying levels of estimated 10-year cardiovascular risk (10%, 15%, 20%) were developed. An existing state-transition Markov model taking a health service perspective and a life-time horizon was adapted to include 3 levels of direct treatment disutility (DTD) associated with ongoing statin use: 0.005, 0.01, and 0.015. For each vignette and DTD we calculated a range of outputs including the payoff time inclusive and exclusive of healthcare costs.

resultsFor a 10% 10-year cardiovascular risk (vignette 1) with low-levels of DTD (0.005), the payoff time was 8.5 years when costs were excluded and 16 years when costs were included. As the baseline risk of cardiovascular increased, the payoff time shortened. For a 15% cardiovascular risk (vignette 2) and for a low-level of DTD, the payoff time was 5.5 years and 9.5 years, respectively. For a 20% cardiovascular risk (vignette 3), the payoff time was 4.2 and 7.2 years, respectively. For higher levels of DTDs for each vignette, the payoff time lengthened, and in some instances the intervention never paid off, leading to an expected net harm for patients.

conclusionsThis study has shown how the payoff time can be readily applied to an existing decision-analytic model and be used to complement existing measures to guide healthcare decision making.

Indexed as

Decision Support TechniquesAgedCardiovascular DiseasesCost-Benefit AnalysisDecision MakingFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMarkov ChainsMiddle AgedPrimary PreventionQuality-Adjusted Life YearsRisk AssessmentRisk FactorsUnited KingdomHydroxymethylglutaryl-CoA Reductase Inhibitorscardiovascularcost-effectivenessdecision-analytic modellingdirect treatment disutilitypayoff time

Identifiers

PMID28441087
PMCPMC5580784

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.